Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ClinicalTrials.gov ID: NCT04920617

Public ClinicalTrials.gov record NCT04920617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Study identification

NCT ID
NCT04920617
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • DPX-Survivac Drug
  • Pembrolizumab Drug
  • CPA Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 17, 2021
Primary completion
Sep 30, 2024
Completion
Mar 31, 2025
Last update posted
Apr 6, 2023

2021 – 2025

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Compassionate Cancer Care Medical Group Fountain Valley California 92708 Recruiting
Boca Raton Regional Hospital Boca Raton Florida 33486 Withdrawn
BRCR Medical Center Inc. Hollywood Florida 33021 Withdrawn
BRCR Medical Center Inc. Plantation Florida 33322 Withdrawn
Comprehensive Hematology and Oncology St. Petersburg Florida 33709 Withdrawn
Blood and Marrow Transplant Group of Georgia Atlanta Georgia 30342 Recruiting
Indiana University Health Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 Recruiting
Tulane Cancer Center Office of Clinical Research New Orleans Louisiana 70112 Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha Nebraska 68130 Recruiting
Christus St. Vincent Regional Cancer Center Santa Fe New Mexico 87505 Recruiting
Brody School of Medicine at East Carolina University Greenville North Carolina 27834 Recruiting
Gabrail Cancer Center Research Canton Ohio 44718 Withdrawn
University of Toledo Medical Center Toledo Ohio 43614 Withdrawn
Toledo Clinic Cancer Center Toledo Ohio 43623 Recruiting
Allegheny Health Network (AHN) West Penn Hospital Pittsburgh Pennsylvania 15224 Recruiting
Reading Hospital - McGlinn Cancer Institute West Reading Pennsylvania 19611 Recruiting
Prairie Lakes Health Care System Watertown South Dakota 57201 Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04920617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04920617 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →